A Closer Look at Psoriatic Arthritis Outcome Measures and Disease Control
Sponsored By AbbVie Medical Affairs
Sep 01, 2020
RA/Inflammatory arthritis
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include:
SELECT-CHOICE study. ABA vs. UPA in…
Autoinflammatory/Still's Disease Panel - EULAR2020
Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Long Delays in Denosumab Increase Fracture Risk (SAT0453). A UK population based study looked at risk of fracture in adults…
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Voclosporin Effective in Lupus Nephritis (OP0277). Voclosporin is a calcineurin inhibitor that has performed well in an earlier…
Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies…
Here is my top-five from day one at EULAR:
Merkel PA, et al. (OP0011) Avacopan as effective as steroids in ANCA Associated Vasculitis (AAV) – 330 patient RCT where AAV was treated with either with…
Updated EULAR Recommendations for RA Management
Dr. Kathryn Dao from EULAR2020 Virtual Conference
Dr. John Cush RheumNow
3 months 1 week ago
Your #RA patients in low disease or remission, do you maintain, reduce or stop DMARDs #EULAR2020
Therapeutic Update
Addressing the heterogeneous manifestations of psoriatic arthritis (PsA) can be challenging for physicians. But how is disease control defined in PsA? What are appropriate treatment targets for use in clinical practice? Join Dr. Alexis Ogdie and Dr. Philip Mease for an overview of composite measures used to assess disease activity and ongoing discussions surrounding disease control and treatment targets for patients with PsA.
Read Post
